Despite many years of research, no biomarkers for stroke are available to use in clinical
practice. Progress in high-throughput technologies has provided new opportunities to …

Background: Distinguishing between stroke subtypes and knowing the time of stroke onset
are critical in clinical practice. Thrombolysis and thrombectomy are very effective treatments …

Stroke is one of the leading causes of disability worldwide. Early diagnosis and treatment of
stroke are important for better clinical outcome. Rapid and accurate diagnosis of stroke …

Biomarkers are objective indicators used to assess normal or pathological processes,
evaluate responses to treatment and predict outcomes. Many blood biomarkers already …

Ergothioneine (ET) is a dietary amino-thione with strong antioxidant and cytoprotective
properties and has possible therapeutic potential for neurodegenerative and vascular …

Objective To validate a panel of blood biomarkers to differentiate between ischemic stroke
(IS) and intracerebral hemorrhage (ICH) in patients with suspected stroke. Methods Patients …

Intracerebral haemorrhage (ICH) is a devastating condition associated with high mortality
and substantial residual disability among survivors. Effective treatments for the acute stages …

Recently included in the 2024 new revised diagnostic criteria of Alzheimer's disease (AD),
glial fibrillary acidic protein (GFAP) has garnered significant attention. A systematic review …

Background Plasma glial fibrillary acidic protein (GFAP) and tau are promising markers for
differentiating acute cerebral ischemia (ACI) and hemorrhagic stroke (HS), but their …

Stroke, a complex and heterogeneous disease, is a leading cause of morbidity and mortality
worldwide. The timely therapeutic intervention significantly impacts patient outcomes, but …